U.S. government agency customer orders upgrade of existing PExA system
PExA AB has received an order from a U.S. government agency customer, which is one of the world’s largest public funders of medical research, for the upgrade of an existing PExA 2.1 system.
The upgrade adds new functionality intended to simplify and improve the efficiency of sample collection and sample handling in the customer’s research activities.
The customer is already using PExA’s technology for non-invasive sampling from the small airways. With this upgrade, sample handling is expected to be substantially simplified and the workflow to become significantly more time-efficient, with considerably less manual handling in connection with sample collection.
The planned work includes continued patient sampling, with proteomics as a prioritized analytical area.
Tomas Gustafsson, CEO of PExA, comments:
“It is very gratifying that one of our U.S. government agency customers is upgrading its PExA system, demonstrating continued and deepened confidence in the technology. This is the first order in which this new functionality is being purchased as an upgrade to an already installed system, and it is very positive to see that our continuous efforts to improve workflow, usability and practical sample handling are appreciated by our customers. The order is also in line with growing interest from government agencies in research.”
The order value amounts to approximately SEK 250,000.
This is an English translation of the original Swedish press release. In the event of any discrepancy, the Swedish original shall prevail.
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 60 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.